Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio

Outlook 2024 - unchanged Outlook 2024 - unchanged   The strategic portfolio includes Sobi's medicines Aspaveli/Empaveli, Doptelet excludingChina, Gamifant, Vonjo and Zynlonta ®, and royalty on Sanofi's sales on Altuviiio™ and Beyfortus. Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session on the same day at16:00 CEST. The presentation can be followed livehere  or afterwards on...

Outlook 2024 - unchanged

 

The strategic portfolio includes Sobi's medicines Aspaveli/Empaveli, Doptelet excluding China, Gamifant, Vonjo and Zynlonta^®, and royalty on Sanofi's sales on Altuviiio™ and Beyfortus.

Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session on the same day at 16:00 CEST.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: +46 8 5051 0031
United Kingdom: +44 207 107 06 13
United States: +1 631 570 56 13

For other countries, please find the details here.

Sobi

Sobi® is a specialised international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 25 April 2024 at 08:00 CEST.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-q1-2024-report--strong-sales-reflecting-the-strength-of-the-portfolio,c3967389

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/sobi-q1-2024-report-strong-sales-reflecting-the-strength-of-the-portfolio-302127110.html